Cancer52 is a briefing paper on the new Cancer Drugs Fund (CDF) operating model. 52 per cent (recent statistics show an increase to 54%) of UK cancer deaths are from the less common cancers. Despite this, rare and less common cancers remain severely under represented and under-funded across all areas, including policy, services and research. Cancer52 is an alliance of 90 organisations working to address this inequality and improve outcomes for patients with these highly challenging diseases.
You can find out more information on our website: http://www.cancer52.org.uk/